PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Conditions

• Crohn Disease

Interventions

• BIOLOGICAL: TNFa Antagonist - Infliximab
• BIOLOGICAL: TNFa Antagonist - Adalimumab
• BIOLOGICAL: Anti-IL12/23 or anti-IL23 - Ustekinumab
• BIOLOGICAL: Anti-IL12/23 or anti-IL23 - Risankizumab
• BIOLOGICAL: Anti-integrin - Vedolizumab IV
• BIOLOGICAL: Anti-integrin - Vedolizumab IV and SC

Sponsor

University of Calgary

Collaborators

• [object Object]